Genflow Biosciences plc announced that In light of the ongoing progress being achieved by Genflow, the Board of Directors has proactively decided to restructure both itself and the Company's Scientific Advisory Board ("SAB"). This step has been taken to align with the Company's current objectives and priorities in the US, including the OTCQB application previously announced, as outlined below: Tamara Joseph, the Company's US-based Non-Executive Director, has been promoted to Chairperson of the Board. Her experience in financing, coupled with her familiarity with the US public markets, will play a crucial role going forward.

Tamara has an impressive track record in public and private financings, having supported Nasdaq financings in excess of $800m. Her expertise in the field of finance is further strengthened by her academic credentials, which include a JD from the University of Michigan Law School and LLM degrees from the College of Europe in Belgium and the University of Paris. Having served as an adviser to the boards of five US publicly traded biotechs, Tamara has demonstrated a strong ability to lead companies.

Her promotion is a recognition of her expertise and strengthens the Company's links with the US market. YassineBendiabdallah, will remain a key member of the Board and will continue to act as a Non-Executive Director. Vera GorbunovaPhD,has been promoted to Chairperson of the SAB.

Dr Gorbunova is an endowed Professor of Biology at the University of Rochester, New York, and Co-Director of the Rochester Ageing Research Center, where her research focuses on the mechanisms of longevity and genome stability, as well as studies on exceptionally long-lived mammals. Throughout her career, Dr. Gorbunova has received numerous awards for her work, including from the Ellison Medical Foundation, the Glenn Foundation, the American Federation for Ageing Research, and the National Institutes of Health. Her research has also been recognized with the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Alianz (France), the Prince Hitachi Prize in Comparative Oncology (Japan), and the Davey Prize from Wilmot Cancer Center.

As Chairperson of the SAB, Dr. Gorbunova's outstanding contributions to the field of longevity and her invaluable insights in this sector will be instrumental in guiding the Company's scientific research. This appointment is a testament to her expertise and achievements in the field. Dr Eric Verdinwill remain a key member of the SAB.

Professor Dr Sven Francque is joining the SAB. Professor Francque is a renowned expert in the field of nonalcoholic fatty liver disease (NAFLD) and its advanced form, nonalcoholic steatohepatitis (NASH). He has a long-standing interest and expertise in NAFLD and NASH, with research focusing on the vascular changes in steatosis and their contribution to disease progression.

Genflow stands to gain significant value from Professor Francque's extensive knowledge of NASH, particularly in identifying new targets and potential therapies for the disease. Moreover, Professor Francque's expertise in clinical research and clinical trial design will be invaluable in the development of clinical trial programs for the Company's novel therapeutics. His membership on the SAB will play a vital role in shaping and broadening the Company's strategy and direction, and his vast experience will be integral to achieving the Company's goal of improving the lives of patients with NAFLD and NASH.